Drug Sponsors

Zambon collaborates with Newron, licenses Parkinson’s treatment

Wednesday, May 16, 2012 10:25 AM

Zambon, an Italian chemical and pharmaceutical company, has formed a strategic collaboration and license agreement with Newron Pharmaceuticals, an R&D company focused on novel CNS and pain therapies, for the latter’s lead compound safinamide.

More... »

Promedior names Suzanne L. Bruhn president and CEO

Wednesday, May 16, 2012 10:08 AM

Promedior, a Malvern, Penn.-based clinical stage biotech developing novel biologic therapeutics for the treatment of fibrosis, has appointed Suzanne L. Bruhn, Ph.D., as president, CEO and to the board of directors.

More... »

BMS and Tsinghua University form strategic partnership

Wednesday, May 16, 2012 09:57 AM

Bristol-Myers Squibb and Tsinghua University of Beijing have entered into a multi-year strategic partnership.

More... »

Cornerstone Therapeutics to acquire EKR Therapeutics

Wednesday, May 16, 2012 09:50 AM

Cornerstone Therapeutics, a specialty pharmaceutical company based in Cary, N.C., will acquire EKR Therapeutics, a Bedminster, N.J-based privately-held specialty pharmaceutical company focused on the acute-care hospital setting.

More... »

Regentis raises $10 million in Series C financing

Monday, May 14, 2012 02:25 PM

Regentis Biomaterials, a privately held company of Princeton, N.J., focused on developing proprietary hydrogels for tissue regeneration, has raised $10 million in its latest round of funding.

More... »

Depomed receives $1 million milestone payment from Ironwood

Friday, May 11, 2012 12:58 PM

Speciality pharmaceutical company Depomed of Menlo Park, Calif., has received a $1 million milestone payment from Ironwood Pharmaceuticals of Cambridge, Mass., following the development and delivery of a prototype formulation of an Ironwood development candidate.

More... »

GSK offers $13 per share for HGS

Wednesday, May 9, 2012 11:46 PM

GlaxoSmithKline will not participate in Human Genome Sciences’ strategic alternatives review process and will instead commence a tender offer this week to acquire all outstanding shares of HGS for $13.00 per share in cash.

More... »

ALS TDI, Regenesance partner on Lou Gehrig’s disease

Monday, May 7, 2012 12:35 PM

Cambridge, Mass.-based ALS Therapy Development Institute (ALS TDI), one of the largest ALS drug development centers, has entered into a partnership with Netherlands-based biotech Regenesance to investigate a potential treatment for Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease.

More... »

NCIC CTG to sponsor, conduct colorectal cancer study for Oncolytics

Friday, May 4, 2012 04:36 PM

Calgary, Alberta-based Oncolytics Biotech has chosen NCIC Clinical Trials Group at Queen's University in Kingston, Ontario, to sponsor and conduct a randomized phase II study of Reolysin in patients with advanced or metastatic colorectal cancer.

More... »

Novartis to acquire Fougera Pharmaceuticals

Friday, May 4, 2012 08:02 AM

Switzerland-based Novartis has signed a definitive agreement to acquire specialty dermatology generics company Fougera Pharmaceuticals of Melville, N.Y., for $1.5 billion in cash.

More... »